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Abstract 
Obesity is increasingly becoming a problem worldwide. Both location and 
metabolic activity of visceral and subcutaneous white adipose tissue (WAT) differ. 
Visceral fat is highly vascularized resulting in increased blood supply and increased 
infiltration of inflammatory immune cells such as macrophages, T cells and even B 
cells. Together with adipocytes these cells secrete adipokines/cytokines that 
propagate an inflammatory milieu locally as well as systemically.  
Obesity is strongly associated with the risk of cardiovascular disease (CVD) – 
diseases affecting the heart and the blood vessels. The underlying pathology of most 
CVDs is termed atherosclerosis, a chronic inflammatory condition of the arterial 
wall. The fatty streak formation is the first step in atherogenesis and is an 
accumulation of lipid-containing cells under the endothelial cell layer, which might 
progress to atheroma formation. Atherosclerotic lesions develop silently without 
symptoms over many years. This can change dramatically when a plaque raptures. 
Occlusion of the artery obstructing the blood flow may cause stroke, myocardial 
infarction or other life-threatening events. 
 
We demonstrate that inflammation of WAT can occur even in the absence of 
obesity. T cell-driven WAT inflammation and obesity-associated inflammation is 
characterized by increased T cell infiltration and expression of pro-inflammatory 
cytokines. Interestingly, IL-6 expression differs in the 2 forms of WAT (paper I).  
We further show the impact of liver-residing inflammatory iNKT cells on lipid 
metabolism, controlling metabolic processes distally in WAT (paper III). We also 
demonstrated the impact of the innate receptor TLR-3 on insulin secretion and 
lipid metabolism (paper IV).  
Changes in lipid metabolism and inflammation contribute to lesion development. 
Different strategies, including immune-modulation and even vaccination, are 
conceivable to prevent, stop or slow down lesion development. The project in my 
thesis that demonstrate the impact of FoxP3+ Tregs on lipid metabolism and 
atherosclerosis (paper II) encourages such work. 
 
Altogether, the findings in my thesis are based on in vitro and in vivo models of 
obesity and atherosclerosis, diseases that can promote each other’s development. 
We broke down the complex processes to study the involvement of single cell types 
(iNKT, FoxP3+ Tregs), receptors (TLR-3), and cytokines (IL-6). Together these 
approaches contribute to the understanding of the molecular mechanisms driving 
these diseases and will hopefully contribute to new therapeutic approaches. 
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